Samsung Will Develop Biosimilars For U.S. And EU, But Avoids Emerging Markets For Now
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Samsung Biologics, which hopes to establish itself as a global contract manufacturer in a long journey to become a global biopharmaceutical company, said it will eventually try to sell its biosimilars in the U.S. and EU markets rather than emerging markets
You may also be interested in...
As Speculation Mounts In Korea, Biosimilar Play Celltrion Still Seems Likely To Sell To Big Pharma
Although Celltrion has raised eyebrows by saying it would consider the best interests of Korea’s pharmaceutical industry in a potential sale, most analysts still believe a multinational will win out. Speculation has heated up after a local report singled out AstraZeneca as a potential suitor.
Korea’s Samsung Biologics Halts Rituxan Biosimilar Trials To Meet U.S, EU Standards
Samsung Biologics halts ongoing clinical trials across 16 countries for its Rituxan biosimilar as it seeks clarity on emerging regulatory guidelines by U.S. FDA.
Korea’s Samsung And Biogen Idec Initiate JV For Global Biosimilars Development
The $300 million Korean joint venture gives Samsung a global stage but raises questions about its Rituxan biosimilars program.